Market Overview
Personalis (PSNL) closed the trading session at 01:24 AM Central Europe on Thursday 22 November 2026, exhibiting a modest increase of 0.38 % over the preceding 24 hours. The share price settled at approximately USD 15.90 on the major exchanges, reflecting a slight upside against the session’s previous close. At the time of reporting, the company’s share supply stood at 107.1 million and its market capitalisation was USD 1.7 billion. In the last day of trading, the volume of Personalis shares exchanged amounted to USD 37.9 million.
Over the month‑end period, the stock has fallen by 1.85 %. A 200‑day simple moving average, a key technical indicator often used to gauge medium‑term trend, sits at USD 11.00. The 52‑week high for the company—USD 18.89—was recorded on 21 August 2026, while the 52‑week low—USD 4.96—was reached on 29 April 2026, indicating a substantial volatility range.
Comparative Performance in the Same 24‑Hour Window
| Stock | Ticker | 24‑Hour Movement | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Kimbell Royalty | KRP | +1.10 % | USD 16.44 | USD 2.0 billion | 19.4 |
| Alpha Metallurgical Resource | AMR | –0.80 % | USD 159.87 | USD 2.0 billion | – |
| Inspire Medical | INSP | +1.70 % | USD 71.07 | USD 2.0 billion | 15.15 |
| Monarch Casino & Resort | MCRI | +0.58 % | USD 113.16 | USD 2.0 billion | 18.2 |
| Northwest Natural | NWN | +1.94 % | USD 48.80 | USD 2.0 billion | 15.91 |
Personalis’ modest gain aligns with a broader, generally positive sentiment for peer firms, though the magnitude of its movement is comparatively modest. Notably, Northwest Natural and Kimbell Royalty posted the largest relative gains within the same period, while Alpha Metallurgical Resource recorded a slight decline.
Company Profile
Personalis Inc. is headquartered in Menlo Park, United States, and operates within the health‑care sector. The company’s core competency lies in genomic sequencing and analytics, providing critical data to accelerate the development of personalized cancer vaccines and other next‑generation immunotherapies. Its services serve a global customer base, and it remains listed on the Nasdaq stock exchange.
For further insight into Personalis’ initiatives and technological offerings, visit their website at www.personalis.com .
